Palliative chemotherapy in patients with refractory and relapsed non-Hodgkin’s lymphomas and Hodgkin’s lymphoma
Kriachok I.A., Titorenko I.B., Kadnikova T., Pastushenko J., Aleksyk O.M., Filonenko Е., Kushchevyi E.V., Ulianchenko K.O., Skripets Т.V.
Summary. The main role of palliative treatment in cancer patients belongs to drug therapy which is more therapeutic than symptomatic and allows to prolong the life of patients for months or even years. Clinical trials show a certain improvements in the quality of life and survival with the help of palliative chemotherapy for non-Hodgkin’s and Hodgkin’s lymphomas. In the hematology department of the National Cancer Institute was studied the toxicity and efficacy of PEPC chemotherapy in patients with relapsed and refractory Hodgkin’s and non-Hodgkin’s lymphoma who were treated with palliative purpose.
Leave a comment